{"id":"amlodipine-hydralazine-terazosin-or-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Peripheral edema"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Hypotension"},{"rate":"5-15","effect":"Hypokalemia"},{"rate":"5-10","effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amlodipine blocks L-type calcium channels to reduce vascular smooth muscle contraction; hydralazine is a direct vasodilator acting on arteriolar smooth muscle; terazosin blocks alpha-1 adrenergic receptors to promote vasodilation; and hydrochlorothiazide is a thiazide diuretic that reduces blood volume and sodium reabsorption. These agents are typically used individually or in combination to achieve additive blood pressure reduction.","oneSentence":"This is a combination of four distinct antihypertensive agents that lower blood pressure through different mechanisms: calcium channel blockade, vasodilation, alpha-1 adrenergic blockade, and diuresis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:25.961Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure (hydralazine component)"}]},"trialDetails":[{"nctId":"NCT02046395","phase":"PHASE4","title":"Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tulane University School of Medicine","startDate":"2012-01","conditions":"Type 2 Diabetes, Hypertension","enrollment":28},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7639,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Norvasc"],"phase":"marketed","status":"active","brandName":"amlodipine, hydralazine, terazosin or hydrochlorothiazide","genericName":"amlodipine, hydralazine, terazosin or hydrochlorothiazide","companyName":"Tulane University School of Medicine","companyId":"tulane-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of four distinct antihypertensive agents that lower blood pressure through different mechanisms: calcium channel blockade, vasodilation, alpha-1 adrenergic blockade, and diuresis. Used for Hypertension, Heart failure (hydralazine component).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}